Trodelvy is Immunomedics’ first approved drug in its nearly four-decade-long corporate history. The biotech’s transition from a research organization to a commercial-stage biotech, though, comes in the middle of a pandemic and at a time when drugmakers have largely grounded traditional in-person sales efforts.
Cancer drugs, though, appear to be less affected by disruption from the spread of the new coronavirus, chiefly due to the critical need for treatment.